Change to a once-daily combination including boosted atazanavir in HIV-1-infected children

Pediatric Infectious Disease Journal

Volumn 25, Issue 9, 2006, Pages 809-814

  Macassa, Eugenia ^a,d   Delaugerre, Constance ^a,d   Teglas, Jean Paul ^b   Jullien, Vincent ^c,d   Tréluyer, Jean Marc ^c,d   Veber, Florence ^a,d   Rouzioux, Christine ^a,d   Blanche, Stéphane ^a,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔPITAL SAINT VINCENT DE PAUL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antiviral; Children; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; JAUNDICE; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; VIROLOGY; VIRUS GENOME; VOMITING;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR; VIRUS REPLICATION;

EID: 33748297583     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000234069.37972.94     Document Type: Article

References (18)

1. Swainston Harrison T, Scott LJ. Atazanavir: A review of its use in the management of HIV infection. Drugs. 2005;65:2309-2336.
2. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44:1035-1050.
3. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immun Defic Syndr. 2005;39:174-180.
4. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189:1802-1810.
5. Pontali E. Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: What are the issues and what can be done? Paediatr Drugs. 2005;7:137-149.
6. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47:1324-1333.
7. Vora S, Marcelin AG, Günthard H, et al. Clinical validation of atazanavir/ritonavir genotypic score in PI-experienced patients. Antiviral Therapy. 2005;10:S9.
8. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretrovviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy. 2000;5:41-48.
9. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-2096.
10. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729-1739.
11. Petersen K, Riddle MS, Jones LE, et al. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS. 2005;19:1700-1702.
12. Ray JE, Marriott D, Bloch MT, McLachlan AJ. Therapeutic drug monitoring of atazanavir: Surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60:291-299.
13. Gianotti N, Seminari E, Guffanti M, et al. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol. 2005;28:119-225.
14. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005;56:380-387.
15. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir and lopinavir/ritonavir in patients experience multiple virological failures. AIDS. 2005;19:685-694.
16. Hill A. Atazanavir/ritonavir versus lopinavir/ritonavir: Equivalent or different efficacy profiles? AIDS. 2005;19:2054-2055.
17. Leon A, Martinez E, Mallolas J, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS. 2005;19:213-215.
18. Masia M, Gutierrez F, Padilla S, Ramos JM, Pascual J. Didanosine-associated toxicity: A predictable complication of therapy with tenofovir and didanosine? J Acquir Immun Defic Syndr. 2004;35:427-428.